Zacks Investment Research
01 Jul 2026, 23:16 UTC · 2h ago
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
01 Jul 2026, 23:16 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
AstraZeneca is projected to report a 15.6% year-over-year growth in EPS of $2.52 for its upcoming July 27, 2026 earnings report. — Strong double-digit earnings growth expectations typically support a bullish outlook for a stock's price ahead of the announcement.
+0.40AstraZeneca currently holds a Zacks Rank of #2 (Buy), supported by a 0.33% upward shift in consensus EPS estimates over the past month. — A 'Buy' rating from a quantitative model based on positive estimate revisions generally signals positive short-term price momentum.
+0.30AstraZeneca's full-year revenue is projected to grow by 7.56% to $63.18 billion. — Steady top-line growth indicates fundamental business expansion, though it is less impactful than the EPS growth projection.
+0.20Continue reading
6 related stories
Search tags
AstraZeneca (AZN) shares fell 3.04% in the most recent trading session, underperforming the S&P 500. — Single-day price drops are often noise, but underperforming the broader index indicates short-term bearish sentiment.
-0.10Which stocks this story touches
The company has a Zacks Rank #2 (Buy) and projected earnings and revenue growth for the upcoming year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
24/7 Wall Street
1h ago
